Shiloh
Editor, Senior Moderator
Source: http://www.cbc.ca/health/story/2009/09/14/h1n1-vaccine-dose.html
1 dose of Canada's H1N1 shot protects adults: company
Last Updated: Monday, September 14, 2009 | 1:50 PM ET
CBC News
A single dose of Canada's vaccine against the H1N1 virus may be enough to protect adults, early results of a clinical trial suggest.
GlaxoSmithKline, which is under contract to produce 50 million vaccine doses for Canada, released the initial results of its first trial on the inoculation on Monday, based on tests on 130 healthy German volunteers aged 18 to 60.
The trial was designed to test the safety and effectiveness of the company's swine flu vaccine, which includes an adjuvant to boost strength and stretch supplies of the serum.
More than 98 per cent of subjects who received a first dose of the vaccine including an adjuvant showed signs of protection three weeks later, compared with 95 per cent of those who received the vaccine without the adjuvant, the company said.
Last week, Australian and U.S. researchers reported similar results for other H1N1 vaccines tested in adults.
The findings mean adults who wish to be vaccinated will have to roll up their sleeves twice this year instead of three times ? once for a seasonal flu shot and again to be inoculated against swine flu.
It's thought that two doses of the swine flu vaccine may be needed for some populations such as children. Studies on children, teens, seniors and people with compromised immune systems are underway to test that theory.
1 dose of Canada's H1N1 shot protects adults: company
Last Updated: Monday, September 14, 2009 | 1:50 PM ET
CBC News
A single dose of Canada's vaccine against the H1N1 virus may be enough to protect adults, early results of a clinical trial suggest.
GlaxoSmithKline, which is under contract to produce 50 million vaccine doses for Canada, released the initial results of its first trial on the inoculation on Monday, based on tests on 130 healthy German volunteers aged 18 to 60.
The trial was designed to test the safety and effectiveness of the company's swine flu vaccine, which includes an adjuvant to boost strength and stretch supplies of the serum.
More than 98 per cent of subjects who received a first dose of the vaccine including an adjuvant showed signs of protection three weeks later, compared with 95 per cent of those who received the vaccine without the adjuvant, the company said.
Last week, Australian and U.S. researchers reported similar results for other H1N1 vaccines tested in adults.
The findings mean adults who wish to be vaccinated will have to roll up their sleeves twice this year instead of three times ? once for a seasonal flu shot and again to be inoculated against swine flu.
It's thought that two doses of the swine flu vaccine may be needed for some populations such as children. Studies on children, teens, seniors and people with compromised immune systems are underway to test that theory.